Sequencing of high-efficacy disease-modifying therapies in multiple sclerosis: perspectives and approaches.

ABSTRACT: Multiple sclerosis (MS) is characterized by chronic inflammation in conjunction with neurodegeneration within the central nervous system. Most individuals with MS begin with a relapsing remitting course that later transitions to secondary progressive MS. Currently available disease-modifying therapies (DMTs) for relapsing MS have been demonstrated to reduce disease activity, however most patients require a change in therapy over the course of their disease. Treatment goals include the prevention of relapses and disability accumulation and to achieve this objective requires careful planning. Sequencing of DMTs for individual patients should be designed in such a way to maximize disease control and minimize risk based on the mechanism of action, pharmacokinetic and pharmacodynamic properties

SUBMITTER: Grand'Maison F 

PROVIDER: S-EPMC6183038 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature